Lycia Therapeutics, Inc.

Lycia Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics designed to degrade disease-causing extracellular proteins. The company leverages a proprietary platform of extracellular protein degradation, specifically through LYTAC (Lysosomal Targeting Chimera) degraders. This innovative technology aims to eliminate the source of disease by targeting and transporting pathogenic proteins into the cell for degradation by the lysosome, utilizing the cell's natural waste disposal process. Lycia Therapeutics' initial focus is on addressing autoimmune, inflammatory, and allergic diseases. Their pipeline includes therapeutic candidates such as LCA-0061 and LCA-0062, which are designed to degrade IgE for the treatment of allergic diseases, including food allergy. Preliminary Phase 1 clinical trial data for LCA-0061 in healthy atopic participants showed rapid, deep, and sustained reduction in total and free IgE. Another program, LCA-0321, targets thyroid-stimulating hormone receptor (TSHR) autoantibodies for Graves' disease. The company's modular and customizable LYTAC platform has the potential to address a broad spectrum of diseases, including some previously considered undruggable. Lycia Therapeutics is headquartered in South San Francisco, CA, US. Sources: [1] https://pitchbook.com/profiles/company/434284-39 [2] https://www.listingtrack.io/company/17272 [3] https://www.renaissancecapital.com/Profile/LYCA/Lycia-Therapeutics/IPO [4] https://www.iposcoop.com/ipo/lyca-therapeutics/ [5] https://mtec-sc.org/life-sciences/lycia-therapeutics [6] https://lyciatx.com/about/overview/ [7] https://lyciatx.com/ [8] https://seekingalpha.com/article/4952923-lycia-therapeutics-launches-us-ipo-for-food-allergy-graves-disease-pipeline